116 related articles for article (PubMed ID: 25629129)
21. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
Tyagi P; Tyagi V
IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
[TBL] [Abstract][Full Text] [Related]
22. Combined treatment with a β
Imamura T; Ogawa T; Minagawa T; Nagai T; Suzuki T; Saito T; Yokoyama H; Nakazawa M; Ishizuka O
Neurourol Urodyn; 2017 Apr; 36(4):1026-1033. PubMed ID: 27367573
[TBL] [Abstract][Full Text] [Related]
23. Urinary incontinence: Novel insights into the mechanism of action of mirabegron on human bladder smooth muscle.
Sidaway P
Nat Rev Urol; 2015 Jun; 12(6):304. PubMed ID: 25917890
[No Abstract] [Full Text] [Related]
24. Involvement of beta(3)-adrenoceptors in mouse urinary bladder function: role in detrusor muscle relaxation and micturition reflex.
Deba A; Palea S; Rouget C; Westfall TD; Lluel P
Eur J Pharmacol; 2009 Sep; 618(1-3):76-83. PubMed ID: 19619525
[TBL] [Abstract][Full Text] [Related]
25. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction.
Füllhase C; Soler R; Westerling-Andersson K; Andersson KE
Neurourol Urodyn; 2011 Sep; 30(7):1382-7. PubMed ID: 21661032
[TBL] [Abstract][Full Text] [Related]
26. Mirabegron, a β
Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
[TBL] [Abstract][Full Text] [Related]
27. Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
Wada N; Shimizu T; Takai S; Shimizu N; Tyagi P; Kakizaki H; Yoshimura N
Neurourol Urodyn; 2017 Apr; 36(4):1039-1045. PubMed ID: 27367752
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cholinergic neurotransmission by β
Silva I; Costa AF; Moreira S; Ferreirinha F; Magalhães-Cardoso MT; Calejo I; Silva-Ramos M; Correia-de-Sá P
Am J Physiol Renal Physiol; 2017 Aug; 313(2):F388-F403. PubMed ID: 28446460
[TBL] [Abstract][Full Text] [Related]
29. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Takasu T; Ukai M; Sato S; Matsui T; Nagase I; Maruyama T; Sasamata M; Miyata K; Uchida H; Yamaguchi O
J Pharmacol Exp Ther; 2007 May; 321(2):642-7. PubMed ID: 17293563
[TBL] [Abstract][Full Text] [Related]
30. Incontinence: How do β
Igawa Y; Aizawa N
Nat Rev Urol; 2017 Jun; 14(6):330-332. PubMed ID: 28322259
[No Abstract] [Full Text] [Related]
31. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats.
Leon LA; Hoffman BE; Gardner SD; Laping NJ; Evans C; Lashinger ES; Su X
J Pharmacol Exp Ther; 2008 Jul; 326(1):178-85. PubMed ID: 18413856
[TBL] [Abstract][Full Text] [Related]
32. TRK-380, a novel selective human β3-adrenoceptor agonist, ameliorates formalin-induced pollakiuria in rats and carbachol-induced bladder contraction in dogs.
Kanie S; Otsuka A; Yoshikawa S; Kobayashi R; Itaba S; Yokokawa H; Tajima Y; Ozono S; Hayashi R; Mochizuki H
Urology; 2013 Oct; 82(4):975.e7-975.e12. PubMed ID: 24075004
[TBL] [Abstract][Full Text] [Related]
33. Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?
Gur S; Peak T; Yafi FA; Kadowitz PJ; Sikka SC; Hellstrom WJ
BJU Int; 2016 Sep; 118(3):464-74. PubMed ID: 27124860
[TBL] [Abstract][Full Text] [Related]
34. β
Igawa Y; Aizawa N; Michel MC
Br J Pharmacol; 2019 Jul; 176(14):2525-2538. PubMed ID: 30868554
[TBL] [Abstract][Full Text] [Related]
35. Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
Kanai A; Wyndaele JJ; Andersson KE; Fry C; Ikeda Y; Zabbarova I; De Wachter S
Neurourol Urodyn; 2011 Jun; 30(5):684-91. PubMed ID: 21661014
[TBL] [Abstract][Full Text] [Related]
36. The actions of isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder.
Persyn S; De Wachter S; Wyndaele JJ; Eastham J; Gillespie J
Auton Neurosci; 2016 Jul; 198():19-27. PubMed ID: 27260964
[TBL] [Abstract][Full Text] [Related]
37. Video-urodynamic effects of mirabegron, a β3 -adrenoceptor agonist, in patients with low-compliance bladder.
Kamei J; Furuta A; Akiyama Y; Niimi A; Ichihara K; Fujimura T; Fukuhara H; Kume H; Homma Y; Igawa Y
Int J Urol; 2015 Oct; 22(10):956-61. PubMed ID: 26177781
[TBL] [Abstract][Full Text] [Related]
38. Mirabegron for overactive bladder.
Belavic JM
Nurse Pract; 2012 Dec; 37(12):9-10. PubMed ID: 23165131
[No Abstract] [Full Text] [Related]
39. Comparison of the effects of β3 -adrenoceptor agonism on urinary bladder function in conscious, anesthetized, and spinal cord injured rats.
Beauval JB; Guilloteau V; Cappellini M; Westfall TD; Rischmann P; Palea S; Gamé X; Lluel P
Neurourol Urodyn; 2015 Aug; 34(6):578-85. PubMed ID: 24938622
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.
Moyes CR; Berger R; Goble SD; Harper B; Shen DM; Wang L; Bansal A; Brown PN; Chen AS; Dingley KH; Di Salvo J; Fitzmaurice A; Gichuru LN; Hurley AL; Jochnowitz N; Miller RR; Mistry S; Nagabukuro H; Salituro GM; Sanfiz A; Stevenson AS; Villa K; Zamlynny B; Struthers M; Weber AE; Edmondson SD
J Med Chem; 2014 Feb; 57(4):1437-53. PubMed ID: 24437735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
